Biolaxy is an innovative biotech company specializing in biopharmaceutical delivery.
Biolaxy was established in 2005 as a wholly owned subsidiary of NOD Pharmaceuticals,
please visit www.nodpharm.com for more information.
The following pages features current news release.  For complete list of press releases,
please visit the archive page.
Nano-particle oral delivery or NOD technology is the core technology used to develop
non-invasive formulation of macromolecular drugs.  For details on NOD technology, please
visit our technology page.

Oral insulin is the leading product candidate being developed at Biolaxy.  For details, please
visit Pipeline.
_______________________________________________________________________________________________________
© All rights reserved.  2005-10  Biolaxy
New & Events
Technology & Products
Biolaxy:
Emerging Leader in Innovative Delivery of Biopharmaceuticals